Dual-specificity CAR-T cells, known as Tan CAR-T cells, targeting MUC1 in combination with an anti-PD-1 antibody showed promise for the treatment of NSCLC (283). This evidence concerns the gene MUC1 and non-small cell lung carcinoma.